Meeting of the Advisory Committee on Blood Safety and Availability, 61143-61144 [2010-24735]
Download as PDF
<![CDATA[
Federal Register / Vol. 75, No. 191 / Monday, October 4, 2010 / Notices
Participation Agreement at
approximately $115 million.
jlentini on DSKJ8SOYB1PROD with NOTICES
VI. The Proposed Complaint
The Commission’s Complaint alleges
that TCCC and DPSG are direct
competitors in the highly concentrated
and difficult to enter (a) branded
concentrate and (b) branded directstore-delivered carbonated soft drink
markets. The concentrate market is
national, and the branded soft drink
markets are local. Total United States
sales of concentrate is about $9 billion,
and total United States sales of
carbonated soft drinks, measured at
retail, is about $70 billion.
To carry out the distribution activities
currently undertaken by the bottler and
contemplated under the license
agreement, DPSG will need to provide
commercially sensitive confidential
information about its marketing plans to
CCR, the newly created TCCC bottler
subsidiary. DPSG currently provides
this sort of information to CCE in order
for it to perform its bottler or
distribution functions. The Commission
is concerned that TCCC’s access to this
information could enable it to use the
information in ways that could impair
DPSG’s ability to compete and
ultimately injure competition by
weakening a competitor or facilitating
coordination in the industry. The
Complaint alleges that TCCC’s access to
DPSG’s confidential information could
eliminate competition between TCCC
and DPSG, increase the likelihood that
TCCC may unilaterally exercise market
power, and facilitate coordinated
interaction in the industry.
VII. The Proposed Consent Order
Under the proposed Consent Order, to
remedy the alleged competitive concern
associated with access to the DPSG
commercially sensitive confidential
information, TCCC will be required to
set up a ‘‘firewall’’ to ensure that persons
at TCCC who may be in a position to use
the DPSG commercially sensitive
information in ways that may injure
DPSG and/or facilitate coordination will
not be allowed access to such
information. Persons at TCCC who are
assigned to perform traditional ‘‘bottler
functions’’– the kinds of functions that
CCE have historically performed for
DPSG – will be permitted access to the
DPSG information. Persons responsible
for ‘‘concentrate-related functions’’– the
kinds of functions that TCCC engaged in
as a competitor of DPSG when both had
their brands distributed by CCE – will
not be permitted access to the DPSG
information.
The proposed Consent Agreement
provides for the appointment of a
VerDate Mar<15>2010
18:22 Oct 01, 2010
Jkt 223001
61143
monitor to assure TCCC’s compliance
with the Consent Order. The monitor
will have a fiduciary responsibility to
the Commission. The monitor will be
appointed for a five (5) year term, but
the Commission may extend or modify
the term as appropriate.
The proposed Consent Agreement
contains a prior notice provision for
subsequent acquisitions by TCCC of its
franchised bottlers that also are licensed
to distribute DPSG products. Under the
order, TCCC will be required to give the
Commission forty-five (45) advance
notice of a proposed acquisition that is
not subject to the Hart-Scott-Rodino Act
and provide the Commission with all
management documents relating to the
proposed acquisition. If the 45-day
period expires without Commission
action, TCCC will be permitted to
consummate the proposed acquisition
and use DPSG confidential information
in the territories of the newly acquired
bottler as specified in this order. The
standard Hart-Scott-Rodino procedures
and time periods would continue to
apply for Hart-Scott-Rodino reportable
transactions.
The order, like the DPSG-TCCC
license agreement, will have a term of
twenty (20) years.
In notice document 2010–23374
beginning on page 57274 in the issue of
Monday, September 20, 2010 make the
following corrections:
1. On page 57275, in the first column,
under the ADDRESSES section, in the
second line, ‘‘(GAO–1O–853G)’’ should
read ‘‘(GAO–10–853G)’’.
2. On the same page, in the same
column, under the ADDRESSES section,
in the third and fourth lines, ‘‘https://
www.gao.gov/govaud/vbkO1.htm.’’
should read ‘‘https://www.gao.gov/
govaud/ybk01.htm.’’.
3. On the same page, in the same
column, under the SUPPLEMENTARY
INFORMATION section, in the seventh line,
‘‘yeJlowbookgao.gov’’ should read
‘‘yellowbook@gao.gov.’’
VIII. Opportunity for Public Comment
Meeting of the Advisory Committee on
Blood Safety and Availability
The Consent Agreement has been
placed on the public record for thirty
(30) days for receipt of comments from
interested persons. Comments received
during this period will become part of
the public record. After thirty days, the
Commission will again review the
proposed Consent Agreement, as well as
the comments received, and will decide
whether it should withdraw from the
Consent Agreement or make final the
Decision and Order.
By accepting the Consent Agreement
subject to final approval, the
Commission anticipates that the
competitive problem alleged in the
Complaint will be resolved. The
purpose of this analysis is to invite and
facilitate public comment concerning
the Consent Agreement. It is not
intended to constitute an official
interpretation of the proposed Consent
Agreement, nor is it intended to modify
the terms of the Decision and Order in
any way.
By direction of the Commission,
Commissioner Ramirez recused.
Donald S. Clark,
Secretary.
[FR Doc. 2010–24838 Filed 10–1–10; 12:10 pm]
BILLING CODE 6750–01–S
PO 00000
Frm 00025
Fmt 4703
Sfmt 4703
GOVERNMENT ACCOUNTABILITY
OFFICE
Financial Management and Assurance;
Government Auditing Standards
Correction
[FR Doc. C1–2010–23374 Filed 10–1–10; 8:45 am]
BILLING CODE 1505–01–D
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Assistant
Secretary for Health, Office of the
Secretary, Department of Health and
Human Services.
ACTION: Notice.
AGENCY:
As stipulated by the Federal
Advisory Committee Act, the U.S.
Department of Health and Human
Services is hereby giving notice that the
Advisory Committee on Blood Safety
and Availability (ACBSA) will hold a
meeting. The meeting will be open to
the public.
DATES: The meeting will take place
Thursday, November 4, and Friday,
November 5, 2010, from 8:30 a.m. to 5
p.m.
ADDRESSES: The Universities at Shady
Grove, 9630 Gudelsky Drive, Rockville,
Maryland 20850, Phone: 301–738–6000.
FOR FURTHER INFORMATION CONTACT: Jerry
A. Holmberg, PhD, Executive Secretary,
Advisory Committee on Blood Safety
and Availability, Office of the Assistant
Secretary for Health, Department of
Health and Human Services, 1101
Wootton Parkway, Suite 250, Rockville,
MD 20852, (240) 453–8803, FAX (240)
453–8456, e-mail ACBSA@hhs.gov.
SUPPLEMENTARY INFORMATION: The
Advisory Committee on Blood Safety
SUMMARY:
E:\FR\FM\04OCN1.SGM
04OCN1
jlentini on DSKJ8SOYB1PROD with NOTICES
61144
Federal Register / Vol. 75, No. 191 / Monday, October 4, 2010 / Notices
and Availability provides advice to the
Secretary and the Assistant Secretary for
Health on a range of policy issues that
includes (1) definition of public health
parameters around safety and
availability of the blood supply and
blood products, (2) broad public health,
ethical and legal issues related to
transfusion and transplantation safety,
and (3) the implications for safety and
the availability of various economic
factors affecting product cost and
supply.
In keeping with its established
mission, the ACBSA will be asked to
review and comment on previous
ACBSA recommendations including
elements of a strategic plan for
transfusion and transplantation safety.
The review is intended to align the
transfusion and transplantation safety
initiatives to the Secretary’s Strategic
Initiatives and Key Inter-Agency
Collaborations: (https://www.hhs.gov/
secretary/about/secretarialstrategic
initiatives2010.pdf).
The Committee will also be asked to
comment and make recommendations
on prioritizing previous and outstanding
recommendations in light of the
Assistant Secretary for Health’s mission
statement: ‘‘Mobilizing Leadership in
Science and Prevention for a Healthier
Nation’’ and strategic priorities: Creating
Better Systems of Prevention;
Eliminating Health Disparities and
Achieving Health Equity; and Making
Healthy People Come Alive for all
Americans.
The public will have opportunity to
present their views to the Committee on
both meeting days. A public comment
session has been scheduled for
November 5, 2010. Comments will be
limited to five minutes per speaker and
must be pertinent to the discussion. Preregistration is required for participation
in the public comment session. Any
member of the public who would like to
participate in this session is encouraged
to contact the Executive Secretary at
his/her earliest convenience to register
for time (limited to 5 minutes) and
registration must be prior to close of
business on November 3, 2010. It is
requested that those who wish to have
printed material distributed to the
Committee provide thirty (30) copies of
the document to the Executive
Secretary, ACBSA, prior to close of
business on November 3, 2010. If it is
not possible to provide 30 copies of the
material to be distributed, then
individuals are requested to provide at
a minimum one (1) copy of the
document(s) to be distributed prior to
the close of business on November 3,
2010. It also is requested that any
member of the public who wishes to
VerDate Mar<15>2010
17:23 Oct 01, 2010
Jkt 223001
provide comments to the Committee
utilizing electronic data projection
submit the necessary material to the
Executive Secretary prior to close of
business on November 3, 2010.
Electronic comments must adhere to
disability accessibility guidelines
(Section 508 compliance).
Dated: September 28, 2010.
Richard A. Henry,
Deputy Executive Secretary, Advisory
Committee on Blood Safety and Availability.
[FR Doc. 2010–24735 Filed 10–1–10; 8:45 am]
BILLING CODE 4150–41–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and
Mental Health Services Administration
(SAMHSA) will publish a summary of
information collection requests under
OMB review, in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
documents, call the SAMHSA Reports
Clearance Officer on (240) 276–1243.
Proposed Project: Evaluation of
Pregnant and Postpartum Women
(PPW) Program
The Substance Abuse and Mental
Health Services Administration
(SAMHSA), Center for Substance Abuse
Treatment (CSAT), is funding 11 fiscal
year (FY) 2009 Services Grants for the
Residential Treatment for Pregnant and
Postpartum Women (PPW) Program.
The purpose of the PPW Program is to
provide cost-effective, comprehensive,
residential treatment services for
pregnant and postpartum women who
suffer from alcohol and other drug use
problems, and for their infants and
children impacted by the perinatal and
environmental effects of maternal
substance use and abuse.
Section 508 [290bb–1] of the Public
Health Service Act mandates the
evaluation and dissemination of
findings of residential treatment
programs for pregnant and postpartum
women. This cross-site accountability
assessment will assess project activities
implemented for these services.
CSAT is requesting approval for a
total of 8,404 burden hours for this new
data collection. CSAT is requesting
approval for a total of 23 instruments.
Of these 23 instruments, 18 instruments
are client-level tools and 5 instruments
PO 00000
Frm 00026
Fmt 4703
Sfmt 4703
are process-level tools. To examine the
effectiveness and impact of the PPW
program, the current design includes
both client-level outcomes and process
evaluation components. The purpose of
the outcome evaluation component is to
examine the extent to which grantees
accomplish the five core goals specified
by the PPW program request for
applications (RFA). These goals include:
• Decrease the use and/or abuse of
prescription drugs, alcohol, tobacco,
illicit and other harmful drugs (e.g.,
inhalants) among pregnant and
postpartum women;
• Increase safe and healthy
pregnancies; improve birth outcomes;
and reduce related effects of maternal
drug abuse on infants and children;
• Improve the mental and physical
health of the women and children;
• Improve family functioning,
economic stability, and quality of life;
and
• Decrease involvement in and
exposure to crime, violence, sexual and
physical abuse, and child abuse and
neglect.
In order to help interpret client-level
outcomes, the process evaluation will
explore what grantees are actually
doing, how well they are doing it, any
challenges encountered, and strategies
grantees used to address them.
Data collection instruments will be
used to collect outcome and process
data for this cross-site accountability
evaluation, program and treatment
planning, and local evaluations. For
clients, data will be collected from
women at four time points (intake, 6months post-intake, discharge, and 6months post-discharge), consistent with
the GPRA data collection schedule. The
schedule for collecting child data is
similar to the mothers, with the addition
of a 3-month post-intake time point. The
following interview instruments will be
used for women, fathers/mother’s
partner, and children:
Women Focused Tools
• BASIS–24® (psychological
symptomology).
• Child Abuse Potential Inventory
(overall risk for child physical abuse).
• Ferrans and Powers Quality of Life
Index (quality of life measure).
• Family Support Scale (helpfulness
of sources of support to parents raising
a young child).
• Women’s Discharge Tool (services
received, length of stay, treatment goals
achieved).
• Staff Completed Women’s Items
(pregnancy status, problems and
outcomes).
• Items Administered to Women
(children residing with mother in
E:\FR\FM\04OCN1.SGM
04OCN1
]]>Agencies
[Federal Register Volume 75, Number 191 (Monday, October 4, 2010)]
[Notices]
[Pages 61143-61144]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-24735]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Meeting of the Advisory Committee on Blood Safety and
Availability
AGENCY: Office of the Assistant Secretary for Health, Office of the
Secretary, Department of Health and Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: As stipulated by the Federal Advisory Committee Act, the U.S.
Department of Health and Human Services is hereby giving notice that
the Advisory Committee on Blood Safety and Availability (ACBSA) will
hold a meeting. The meeting will be open to the public.
DATES: The meeting will take place Thursday, November 4, and Friday,
November 5, 2010, from 8:30 a.m. to 5 p.m.
ADDRESSES: The Universities at Shady Grove, 9630 Gudelsky Drive,
Rockville, Maryland 20850, Phone: 301-738-6000.
FOR FURTHER INFORMATION CONTACT: Jerry A. Holmberg, PhD, Executive
Secretary, Advisory Committee on Blood Safety and Availability, Office
of the Assistant Secretary for Health, Department of Health and Human
Services, 1101 Wootton Parkway, Suite 250, Rockville, MD 20852, (240)
453-8803, FAX (240) 453-8456, e-mail ACBSA@hhs.gov.
SUPPLEMENTARY INFORMATION: The Advisory Committee on Blood Safety
[[Page 61144]]
and Availability provides advice to the Secretary and the Assistant
Secretary for Health on a range of policy issues that includes (1)
definition of public health parameters around safety and availability
of the blood supply and blood products, (2) broad public health,
ethical and legal issues related to transfusion and transplantation
safety, and (3) the implications for safety and the availability of
various economic factors affecting product cost and supply.
In keeping with its established mission, the ACBSA will be asked to
review and comment on previous ACBSA recommendations including elements
of a strategic plan for transfusion and transplantation safety. The
review is intended to align the transfusion and transplantation safety
initiatives to the Secretary's Strategic Initiatives and Key Inter-
Agency Collaborations: (https://www.hhs.gov/secretary/about/secretarialstrategicinitiatives2010.pdf).
The Committee will also be asked to comment and make
recommendations on prioritizing previous and outstanding
recommendations in light of the Assistant Secretary for Health's
mission statement: ``Mobilizing Leadership in Science and Prevention
for a Healthier Nation'' and strategic priorities: Creating Better
Systems of Prevention; Eliminating Health Disparities and Achieving
Health Equity; and Making Healthy People Come Alive for all Americans.
The public will have opportunity to present their views to the
Committee on both meeting days. A public comment session has been
scheduled for November 5, 2010. Comments will be limited to five
minutes per speaker and must be pertinent to the discussion. Pre-
registration is required for participation in the public comment
session. Any member of the public who would like to participate in this
session is encouraged to contact the Executive Secretary at his/her
earliest convenience to register for time (limited to 5 minutes) and
registration must be prior to close of business on November 3, 2010. It
is requested that those who wish to have printed material distributed
to the Committee provide thirty (30) copies of the document to the
Executive Secretary, ACBSA, prior to close of business on November 3,
2010. If it is not possible to provide 30 copies of the material to be
distributed, then individuals are requested to provide at a minimum one
(1) copy of the document(s) to be distributed prior to the close of
business on November 3, 2010. It also is requested that any member of
the public who wishes to provide comments to the Committee utilizing
electronic data projection submit the necessary material to the
Executive Secretary prior to close of business on November 3, 2010.
Electronic comments must adhere to disability accessibility guidelines
(Section 508 compliance).
Dated: September 28, 2010.
Richard A. Henry,
Deputy Executive Secretary, Advisory Committee on Blood Safety and
Availability.
[FR Doc. 2010-24735 Filed 10-1-10; 8:45 am]
BILLING CODE 4150-41-P
